Table of Contents Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82 ...

Table of Contents Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET Company Participants Stuart Henderson - Vice President, Corporate Development & Investor Relations Will Chou - Chief Executive Officer Mark Forman - Chief Medical Officer Simona King - Chief Financial Officer Conference Call Participants Brendan Smith - Cowen Omari Baruti - Goldman Sachs Laura Chico - Wedbush Yun Zhong - BTIG Whitney Ijem - Canaccord Operator Good morning, and welcome to the Passage Bio Fourth Quarter ...

To fulfill the promise of genetic medicine by developing transformative therapies for people with devastating CNS diseases Deep experience in rare disease, CNS disorders and genetic medicines LEADERSHIP TEAM William Chou, M.D. Chief Executive Officer Desiree Luthman, D.D.S. SVP Global Regulatory Affairs Alex Fotopoulos Chief Technology Officer Mark Forman, M.D., Ph.D. Chief Medical Officer O A C A D I Simona King Chief Financial Officer Chip Cale General Counsel & Corporate Secretary BOARD OF DIRECTORS Maxi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39231 PASSAGE BIO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-2729751 (State or other ...

Fulfilling the Promise of Genetic Medicines for Central Nervous System Disorders Corporate Presentation November 2022 NASDAQ GS: PASG 2 Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned progress of clinical trials and the availa ...

Passage Bio, Inc. (NASDAQ:PASG) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Stuart Henderson - VP, Corporate Development and Investor Relations William Chou - Chief Executive Officer Mark Forman - Chief Medical Officer Simona King - Chief Financial Officer Conference Call Participants Brendan Smith - Cowen Neena Bitritto-Garg - Citi Laura Chico - Wedbush Danielle Brill - Raymond James Yun Zhong - BTIG Operator Good morning and welcome to the Passage Bio Third Quarter ...

Fulfilling the Promise of Genetic Medicines for Central Nervous System Disorders Corporate Presentation August 2022 NASDAQ GS: PASG 2 Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned initiation of clinical trials and the availa ...

Passage Bio, Inc. (NASDAQ:PASG) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona King - CFO Mark Forman - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen Neena Bitritto-Garg - Citi Alex Nackenoff - Raymond James Laura Chico - Wedbush Operator Good morning and welcome to the Passage Bio Second Quarter 2022 Financial and Operating Results Conference Call. [Operator Inst ...

Passage Bio, Inc. (NASDAQ:PASG) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Stuart Henderson - Vice President of Corporate Development and Investor Relations Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Tessa Romero - JPMorgan Neena Bitritto-Garg - Citi Brendan Smith - Cowen & Company Daniel Brill - Raymond James Operator Thank you f ...